We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Showcases Innovative Laboratory Solutions and Digital Diagnostics

By LabMedica International staff writers
Posted on 21 May 2023

Roche Diagnostics (Basel, Switzerland) is showcasing innovative laboratory solutions and digital diagnostics through - "Innovation Past, Present and Future" at this year's WorldLab-EuroMedLab 2023 in Rome, Italy, 21-25 May. More...

Attendees can experience first-hand Roche's latest technological advancements in lab automation, serum work area, molecular and point of care solutions, and discover how the company is transforming patient care through advancements in breakthrough high-medical value diagnostic and digital solutions.

At the 2023 EuroMedLab Congress, Roche is featuring new innovations, such as several molecular systems from the growing PCR portfolio – the cobas 5800 and the new LightCycler PRO System, which will be launched later this year. A prototype for the new cobas Mass Spec system is being unveiled, bringing mass spectrometry into the routine testing environment. The system complements the serum work area portfolio, allowing healthcare communities to benefit in the future from an extended diagnostic platform offering clinical chemistry, heterogeneous immunoassays, and mass spectrometry.

The new cobas connection modules (CCM Vertical), a flexible modular system that makes effective utilization of lab space and seamlessly integrates into the existing cobas connection modules, improving lab efficiency, is also being featured at the industry event. Roche is also introducing its navify digital solutions to the laboratory community that are designed to fulfill the laboratories' need for seamless and secure connectivity between systems, instruments and even devices from different providers, as well as empowering lab leaders to drive operational efficiencies and help clinicians gain greater medical insights.

"With the ever-changing needs of the healthcare system, laboratories, and clinicians are expected to optimize laboratory operations and efficiencies while improving patient care," said Ann Costello, Head of Roche Diagnostics Solutions at Roche Diagnostics. "We are pleased to present the next generation of innovative solutions that simplify and streamline testing for laboratories of all sizes, throughputs, and disciplines while supporting clinical decision-making to improve patient care."

"Laboratories have a unique opportunity to connect siloed data across systems and points of care for greater insights," said Moritz Hartmann, Head of Roche Information Solutions at Roche Diagnostics. "At Roche, we are working closely together with lab leaders to enable more patient-centered care. Our navify portfolio of integrated digital solutions enables open digital ecosystems that connect to innovations, drive operational efficiencies, and generate actionable insights for improved patient care."

Related Links:
Roche Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.